The effect on work loss of different treatments for rheumatoid arthritis

Treatment with a biological agent was not superior to conventional treatment in terms of the effect on work loss over 21 months in patients with early rheumatoid arthritis (RA) who responded insufficiently to methotrexate, according to a report published by JAMA Internal Medicine.

The introduction of biological inhibitors has improved the treatment of RA but at a substantial cost, according to the study background.

From a , Jonas K. Eriksson, M.Sc., of the Karolinska Institutet, Sweden, and colleagues measured monthly sick leave and disability pension days in patients who did not achieve low disease activity after three to four months of methotrexate therapy. The patients were divided into groups to receive additional biological treatment with or conventional combination treatment with sulfasalazine plus . Of 204 eligible patients, 105 were assigned to biological and 99 to conventional treatment.

The baseline average work loss was 17 days per month in both groups. The average changes in work loss at 21 months were -4.9 days per month in the biological and -6.2 days per month in the conventional treatment group, according to the study results.

"Our analysis showed that early and aggressive treatment in methotrexate-resistant patients not only stops the trend of increasing work loss days, as in patients with mainly established RA, but partly reverses it. However, we did not find any difference between treatment arms, indicating that the significantly improved disease control associated with infliximab treatment over a one-year period and the better radiological results after two years did not translate into less work loss," the study concludes. "The substantially higher cost of infliximab relative to conventional treatment needs to be weighed against the greater incidence of short-term adverse events leading to discontinuation of conventional treatment."

More information: JAMA Intern Med. Published online July 1, 2013. doi:10.1001/jamainternmed.2013.7801

add to favorites email to friend print save as pdf

Related Stories

Data suggest smoking doesn't impact RA treatment response

Dec 21, 2012

(HealthDay)—For patients with early rheumatoid arthritis (RA), smoking status does not impact treatment response to early combination therapy or initial methotrexate treatment with step-up therapy, according ...

Early and aggressive arthritis treatment recommended

Jun 23, 2010

Disease-modifying antirheumatic drugs (DMARDs) should be used early and aggressively at the first sign of rheumatoid arthritis (RA). The results of an 11-year trial, published in BioMed Central's open access journal Arthritis Re ...

Recommended for you

Uranium exposure tied to lupus

Aug 20, 2014

(HealthDay)—High uranium exposure is associated with systemic lupus erythematosus (SLE), according to a study published online Aug. 7 in Arthritis & Rheumatology.

User comments